Here you'll find latest insights on our work at Orchestra BioMed, featuring original articles, one-pagers, and videos, keeping you in sync with our pipeline programs, market opportunities, and industry perspectives
A 2-minute look into how Orchestra BioMed is redefining treatment approaches with bold partnerships and cutting-edge research
Watch Now
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
Orchestra BioMed Announces Proposed Public Offering
Orchestra BioMed Announces Pricing of $40 Million Public Offering
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transacti...
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding...
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Avi Fischer, M.D., joined forward-thinking leaders exploring the future of treating hypertensive hea...
Great ideas need great minds to bring them to life. Our team is dedicated to making a lasting impact...
Where in the world is our CEO? 🌍 David Hochman joined leading voices in hashtag#Cardiology and hash...
Ligand Pharmaceuticals and Medtronic Cardiac and Vascular commit $70 Million in strategic capital to...
FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT glo...
